Beam Therapeutics will use the funds to drive the development of next-generation CRISPR technologies. Credit: typographyimages via Pixabay.

US-based precision genetic medicines developer Beam Therapeutics has raised $135m in a series B funding round to drive the development of next-generation CRISPR technologies.

The company also intends to use the funds to expand its base pipeline of gene-editing programmes as well as boost its scientific and technical leadership.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Redmile Group, Cormorant Asset Management, GV and Altitude Life Science Ventures participated in the financing round, which was joined by F-Prime Capital, ARCH Venture Partners, Eight Roads Ventures, Omega Funds and other undisclosed investors.

Beam is engaged in the development of treatments for serious diseases using its base editing technology that is designed to make precise edits to single base pairs in DNA and RNA. It is currently working on ten active programmes.

Beam Therapeutics CEO John Evans said: “Since the launch of Beam last year, we have made significant progress toward our goal of developing base editors as a new class of precision genetic medicines.

“With this funding, we will continue to expand our team and capabilities, extend our leadership position in base editing technology, and move our pipeline towards clinical development where we hope to make an impact for patients with serious genetic diseases.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“More than 50% of disease-causing genetic errors are due to a single-letter alteration in the nucleobases of the human genome.”

The company noted that more than 50% of disease-causing genetic errors are due to a single-letter alteration in the nucleobases of the human genome.

However, some natural genetic variations in DNA are associated with protection from diseases.

Beam Therapeutics’ technologies could edit the genome to eliminate errors or write in protective changes at the single letter level and thereby avoiding cutting the DNA or RNA strands.

This base editing approach for precise genome modification is expected to help prevent, modify and potentially cure a variety of diseases.

Beam Therapeutics obtained a worldwide licence to develop and commercialise the DNA base editing platform from Harvard University in May last year.